Search

Your search keyword '"Biran, Noa"' showing total 448 results
Start Over Author "Biran, Noa"
448 results on '"Biran, Noa"'

1. Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study

Author

Biran, Noa, Anthony Kouyaté, Robin, Yucel, Emre, McGovern, Gillian E, Schoenthaler, Antoinette M, Durling, Olivia G, Unawane, Rashmi, Schutt, Andrew, and Panjabi, Sumeet

Subjects
Medicine
Abstract

BackgroundRelapsed and refractory multiple myeloma (RRMM) is a bone marrow cancer that requires systemic treatment, which often results in severe symptom burden. Recent studies have found that electronic patient-reported outcome (ePRO) interventions implemented in the clinic setting have had positive outcomes for other oncology populations. Evidence of the efficacy of a similar approach is lacking for patients with RRMM. ObjectiveRecent recommendations for digital health interventions call for the publication of descriptions of iterative development processes in order to improve reproducibility and comparability. This study is an implementation pilot aiming to evaluate the acceptability and appropriateness of an ePRO intervention for patients with RRMM and to explore its impact on clinic workflow. MethodsA total of 11 patients with RRMM were recruited from the John Theurer Cancer Center in Hackensack, New Jersey. Patients used a mobile app to report on 17 symptoms at 4 sessions, each a week apart. Patients could also report symptoms ad hoc. When reports met predefined thresholds, the clinic was alerted and patients received automated guidance. Study end points were assessed using qualitative and quantitative methods. ResultsA total of 9 patients (mean age 69.7 years) completed the study. Overall, 83% (30/36) of weekly sessions were completed. Patients found the frequency and time required to complete reporting acceptable. All patients agreed that the app was easy to use and understand. Providers felt the alerts they received required refinement. Patients and providers agreed it would be beneficial for patients to report for longer than 4 weeks. Patients felt that the training they received was adequate but contained too much information for a single session. All patients found the symptoms tracked to be appropriate; providers suggested shortening the list. All patients understood how to use the app for weekly reporting but had confusion about using it ad hoc. Providers felt the ad hoc feature could be removed. Neither patients nor providers viewed the in-app data reports but agreed on their potential value. Patients reported benefitting from symptom reporting through increased awareness of their symptoms. Clinic staff reported that app alerts were too numerous and redundant. They had difficulty responding to alerts within their existing workflow, partially because the data were not integrated into the electronic medical record system. ConclusionsOverall, the intervention was found to be acceptable and appropriate for patients with RRMM. Points of friction integrating the intervention into the clinic workflow were identified. Clinic staff provided recommendations for addressing these issues. Once such modifications are implemented, ePRO data from patients with RRMM could be used to inform and improve clinical research and care. This study underlines the importance of an iterative approach to implementation that includes all stakeholders in order to ensure successful adoption.

Published
2020
Full Text
View/download PDF

2. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Author

Gasparetto, Cristina, Schiller, Gary J, Tuchman, Sascha A, Callander, Natalie S, Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C, Kotb, Rami, White, Darrell, Bahlis, Nizar J, Chen, Christine I, Sutherland, Heather J, Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P, Bensinger, William I, Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Lipe, Brea

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Cancer, Hematology, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Administration Schedule, Female, Humans, Hydrazines, Male, Maximum Tolerated Dose, Middle Aged, Multiple Myeloma, Oligopeptides, Survival Analysis, Translocation, Genetic, Treatment Outcome, Triazoles, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundProteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM).MethodsThe safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100 mg) + carfilzomib (56 or 70 mg/m2) + dexamethasone (40 mg) (XKd) once weekly (QW) was evaluated in patients with relapsed refractory MM (RRMM) not refractory to carfilzomib.ResultsThirty-two patients, median prior therapies 4 (range, 1-8), were enrolled. MM was triple-class refractory in 38% of patients and 53% of patients had high-risk cytogenetics del(17p), t(4;14), t(14;16) and/or gain 1q. Common treatment-related adverse events (all/Grade 3) were thrombocytopenia 72%/47% (G3 and G4), nausea 72%/6%, anaemia 53%/19% and fatigue 53%/9%, all expected and manageable with supportive care and dose modifications. MTD and RP2D were identified as selinexor 80 mg, carfilzomib 56 mg/m2, and dexamethasone 40 mg, all QW. The overall response rate was 78% including 14 (44%) ≥ very good partial responses. Median progression-free survival was 15 months.ConclusionsWeekly XKd is highly effective and well-tolerated. These data support further investigation of XKd in patients with MM.

Published
2022

5. Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma

Author

Martin, Thomas G, Shah, Nina, Richter, Joshua, Vesole, David H, Wong, Sandy W, Huang, Chiung‐Yu, Madduri, Deepu, Jagannath, Sundar, Siegel, David S, Biran, Noa, Wolf, Jeffrey L, Parekh, Samir, Cho, Hearn J, Munster, Pamela, Richard, Shambavi, Ziti‐Ljajic, Samira, and Chari, Ajai

Subjects
Rare Diseases, Immunization, Patient Safety, Clinical Research, Biotechnology, Clinical Trials and Supportive Activities, Cancer, Hematology, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Oligopeptides, Recurrence, carfilzomib, isatuximab, immunomodulatory, monoclonal antibody, pharmacokinetics, proteasome, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundIsatuximab (Isa), an anti-CD38 monoclonal antibody, and carfilzomib (K), a next-generation proteasome inhibitor (PI), both have potent single-agent activity in relapsed and refractory multiple myeloma (RRMM).MethodsThis phase 1b study evaluated the combination of Isa and K in 33 patients with RRMM. Isa was administered by intravenous infusion in 3 dosing cohorts: dose level 1 (Isa at 10 mg/kg biweekly), dose level 2 (DL2; Isa at 10 mg/kg weekly for 4 doses and then biweekly), and dose level 3 (Isa at 20 mg/kg weekly for 4 doses and then biweekly) and all patients received K (20 mg/m2 intravenously for cycle 1, days 1 and 2, and then 27 mg/m2 for all subsequent doses). A standard 3+3 dose-escalation design was used, no dose-limiting toxicity was observed, and the maximum tolerated dose was not reached. An expansion cohort of 18 patients was enrolled at DL2 to further evaluate safety and efficacy. Responses were assessed with the International Myeloma Working Group response criteria, and patients continued treatment until disease progression or unacceptable toxicity.ResultsWith a median follow-up of 26.7 months, in this heavily pretreated population with a median of 3 prior lines (refractory to PIs and immunomodulatory drugs, 76%; refractory to K, 27%), the overall response rate was 70% (stringent complete response/complete response, 4; very good partial response, 8; partial response, 11). The median progression-free survival was 10.1 months, and the 2-year survival probability was 76%. The most common treatment-related adverse events (grade 2 or higher) were anemia, leukopenia, neutropenia, thrombocytopenia, hypertension, and infection. Infusion reactions were common (55%) but did not limit dosing.ConclusionsTreatment with Isa plus K was well tolerated with no unexpected toxicity. The combination was effective despite the enrollment of heavily pretreated patients with RRMM.Lay summaryThis phase 1b study was designed to assess the safety, pharmacokinetics, and preliminary efficacy of isatuximab and carfilzomib in patients with relapsed and refractory multiple myeloma. Thirty-three patients were treated: 15 in dose escalation and 18 in dose expansion. Patients received an average of 10 cycles. The treatment was safe and effective. No unexpected toxicity or drug-drug interactions were noted. Seventy percent of the subjects responded to therapy, and the progression-free survival was 10.1 months.

Published
2021

6. Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.

Author

Richardson, Paul, Jagannath, Sundar, Chari, Ajai, Vogl, Dan, Dimopoulos, Meletios, Moreau, Philippe, Dingli, David, Wei, Lee-Jen, Richter, Joshua, Biran, Noa, Siegel, David, Reichmann, William, Li, Lingling, Tang, Shijie, Saint-Martin, Jean-Richard, Joshi, Anita, Kauffman, Michael, Shah, Jatin, Shacham, Sharon, and Lonial, Sagar

Subjects
multiple myeloma, selective inhibitor of nuclear export, selinexor, triple‐class‐refractory multiple myeloma
Abstract

Triple-class-refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low-dose dexamethasone (Sel-dex) demonstrated a 26.2% overall response rate in triple-class-refractory MM. Here, we compare overall survival (OS) of 122 patients with triple-class-refractory MM who received Sel-dex in STORM Part 2 with that of 64 similar patients treated with other available therapies in a Flatiron Health Analytic Database (FHAD) cohort. OS from the date that the patients MM became triple-class-refractory was longer in STORM versus FHAD, with an unadjusted hazard ratio (HR) of 0.43 (P =  .0002; adjusted HR 0.35 [P  =  .011]). In a subset analysis of highly resistant patients receiving further therapies after their MM first became at least triple-class-refractory (i.e., who received Sel-dex in STORM, n = 64, and non-Sel-dex in FHAD, n = 36), the OS was significantly longer in STORM with an unadjusted HR of 0.52 (P = .0331; adjusted HR 0.33 [P = .041]). Within the limits of this analysis, the OS of patients with at least triple-class-refractory MM was significantly better with Sel-dex versus available therapies, suggesting that Sel-dex may be associated with a meaningful OS benefit in these patients.

Published
2021

7. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies

Author

Schiller, Gary J., Lipe, Brea C., Bahlis, Nizar J., Tuchman, Sascha A., Bensinger, William I., Sutherland, Heather J., Lentzsch, Suzanne, Baljevic, Muhamed, White, Darrell, Kotb, Rami, Chen, Christine I., Rossi, Adriana, Biran, Noa, LeBlanc, Richard, Grosicki, Sebastian, Martelli, Maurizio, Gunsilius, Eberhard, Špička, Ivan, Stevens, Don Ambrose, Facon, Thierry, Mesa, Mercedes Gironella, Zhang, Chris, Van Domelen, Dane R., Bentur, Ohad S., and Gasparetto, Cristina

Published
2023
Full Text
View/download PDF

10. Real-world outcomes (RWO) with tandem transplantation in patients (pts) with newly diagnosed multiple myeloma (NDMM).

Author

Parmar, Harsh, primary, Barcellos, Anna, additional, Biran, Noa, additional, Phull, Pooja, additional, Vesole, David H., additional, Belli, Andrew J., additional, Fernandes, Laura L., additional, Hansen, Eric, additional, Zettler, Christina, additional, Wang, Ching-Kun, additional, Goran, Stefanie, additional, Anderson, Courtney, additional, Doucette, Kimberley, additional, Gunning, Thomas S, additional, Ip, Andrew, additional, and Siegel, David Samuel DiCapua, additional

Published
2024
Full Text
View/download PDF

11. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Author

Dhakal, Binod, Shah, Nina, Kansagra, Ankit, Kumar, Ambuj, Lonial, Sagar, Garfall, Alfred, Cowan, Andrew, Poudyal, Bishesh Sharma, Costello, Caitlin, Gay, Francesca, Cook, Gordon, Quach, Hang, Einsele, Herman, Schriber, Jeff, Hou, Jian, Costa, Luciano, Aljurf, Mahmoud, Chaudhry, Maria, Beksac, Meral, Prince, Miles, Mohty, Mohamad, Janakiram, Murali, Callander, Natalie, Biran, Noa, Malhotra, Pankaj, Otero, Paula Rodriguez, Moreau, Philippe, Abonour, Rafat, Iftikhar, Raheel, Silberman, Rebecca, Mailankody, Sham, Gregory, Tara, Lin, Yi, Carpenter, Paul, Hamadani, Mehdi, Usmani, Saad, and Kumar, Shaji

Published
2022
Full Text
View/download PDF

15. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Author

Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, García Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María-Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., and Avet-Loiseau, Hervé

Published
2020
Full Text
View/download PDF

16. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Author

Biran, Noa, Ip, Andrew, Ahn, Jaeil, Go, Ronaldo C, Wang, Shuqi, Mathura, Shivam, Sinclaire, Brittany A, Bednarz, Urszula, Marafelias, Michael, Hansen, Eric, Siegel, David S, Goy, Andre H, Pecora, Andrew L, Sawczuk, Ihor S, Koniaris, Lauren S, Simwenyi, Micky, Varga, Daniel W, Tank, Lisa K, Stein, Aaron A, Allusson, Valerie, Lin, George S, Oser, William F, Tuma, Roman A, Reichman, Joseph, Brusco, Louis, Jr, Carpenter, Kim L, Costanzo, Eric J, Vivona, Vincent, and Goldberg, Stuart L

Published
2020
Full Text
View/download PDF

18. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Author

Tremblay, Gabriel, Daniele, Patrick, Breeze, Janis, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Engelhardt, Monika, Chari, Ajaj, Nooka, Ajay, Vogl, Dan, Gavriatopoulou, Maria, Dimopoulos, Meletios-Athanasios, Richardson, Paul, Biran, Noa, Siegel, David, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Mohty, Mohamad, Meuleman, Nathalie, Levy, Moshe, Costa, Luciano, Hoffman, James E., Delforge, Michel, Kaminetzky, David, Weisel, Katja, Raab, Marc, Dingli, David, Tuchman, Sascha, Laurent, Frenzel, Vij, Ravi, Schiller, Gary, Moreau, Philippe, Richter, Joshua, Schreder, Martin, Podar, Klaus, Parker, Terri, Cornell, Robert Frank, Lionel, Karlin, Choquet, Sylvain, and Sundar, Jagannath

Published
2021
Full Text
View/download PDF

19. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.

Author

Adomako, Alfred, Calvo, Veronica, Biran, Noa, Osman, Keren, Chari, Ajai, Paton, James, Paton, Adrienne, Moore, Kateri, Schewe, Denis, and Aguirre-Ghiso, Julio

Subjects
Adult, Aged, Animals, Apoptosis, Azacitidine, Bortezomib, Cell Survival, Cyclin-Dependent Kinase 6, Endoplasmic Reticulum Chaperone BiP, Female, Gene Expression Regulation, Neoplastic, Heat-Shock Proteins, Humans, Male, Mice, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Xenograft Model Antitumor Assays, p21-Activated Kinases
Abstract

BACKGROUND: The mechanisms allowing residual multiple myeloma (MM) cells to persist after bortezomib (Bz) treatment remain unclear. We hypothesized that studying the biology of bortezomib-surviving cells may reveal markers to identify these cells and survival signals to target and kill residual MM cells. METHODS: We used H2B-GFP label retention, biochemical tools and in vitro and in vivo experiments to characterize growth arrest and the unfolded protein responses in quiescent Bz-surviving cells. We also tested the effect of a demethylating agent, 5-Azacytidine, on Bz-induced quiescence and whether inhibiting the chaperone GRP78/BiP (henceforth GRP78) with a specific toxin induced apoptosis in Bz-surviving cells. Finally, we used MM patient samples to test whether GRP78 levels might associate with disease progression. Statistical analysis employed t-test and Mann-Whitney tests at a 95% confidence. RESULTS: We report that Bz-surviving MM cells in vitro and in vivo enter quiescence characterized by p21(CIP1) upregulation. Bz-surviving MM cells also downregulated CDK6, Ki67 and P-Rb. H2B-GFP label retention showed that Bz-surviving MM cells are either slow-cycling or deeply quiescent. The Bz-induced quiescence was stabilized by low dose (500nM) of 5-azacytidine (Aza) pre-treatment, which also potentiated the initial Bz-induced apoptosis. We also found that expression of GRP78, an unfolded protein response (UPR) survival factor, persisted in MM quiescent cells. Importantly, GRP78 downregulation using a specific SubAB bacterial toxin killed Bz-surviving MM cells. Finally, quantification of Grp78(high)/CD138+ MM cells from patients suggested that high levels correlated with progressive disease. CONCLUSIONS: We conclude that Bz-surviving MM cells display a GRP78(HIGH)/p21(HIGH)/CDK6(LOW)/P-Rb(LOW) profile, and these markers may identify quiescent MM cells capable of fueling recurrences. We further conclude that Aza + Bz treatment of MM may represent a novel strategy to delay recurrences by enhancing Bz-induced apoptosis and quiescence stability.

Published
2015

21. P-328 Talquetamab vs real-world physician's choice of therapy (RWPC): comparative efficacy in patients (pts) with triple-class exposed (TCE) relapsed/ refractory multiple myeloma (RRMM)

Author

Ye, Jing Christine, primary, Biran, Noa, additional, Nair, Sandhya, additional, Lin, Xiwu, additional, Qi, Keqin, additional, Londhe, Anil, additional, Ammann, Eric, additional, Renaud, Thomas, additional, Kane, Colleen, additional, Parekh, Trilok, additional, Gray, Kathleen, additional, Peterson, Steve, additional, and Costa, Luciano, additional

Published
2023
Full Text
View/download PDF

24. P1681: RACIAL DIFFERENCES IN DETERMINANTS OF TREATMENT DECISION-MAKING AMONG PATIENTS WITH MULTIPLE MYELOMA

Author

Dwyer, Lisa, primary, Lin, Dee, additional, Wu, Bingcao, additional, Biran, Noa, additional, Faiman, Beth, additional, Ahlstrom, Jennifer, additional, Herout, Peter, additional, Deering, Kathleen, additional, Yung, Margaret, additional, Kulbokas, Victoria, additional, Feldman, Josh, additional, Kline, Erika D, additional, and Leblanc, Thomas W, additional

Published
2023
Full Text
View/download PDF

25. P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY

Author

Tan, Carlyn, primary, Searle, Emma, additional, Anguille, Sébastien, additional, Bhutani, Manisha, additional, Biran, Noa, additional, Boyd, Kevin, additional, Cowan, Andrew, additional, Matous, Jeffrey, additional, Perrot, Aurore, additional, Berdeja, Jesus, additional, Janowski, Wojciech, additional, Popat, Rakesh, additional, Quach, Hang, additional, Schroeder, Mark, additional, Wong, Sandy W, additional, Vishwamitra, Deeksha, additional, Guo, Yue, additional, Niu, Zhuolu, additional, Larsen, Julie, additional, Chen, Lingling, additional, Banerjee, Arnob, additional, and Touzeau, Cyrille, additional

Published
2023
Full Text
View/download PDF

26. P1690: SHARED DECISION-MAKING IN MULTIPLE MYELOMA: DO PATIENTS, CAREGIVERS, AND PHYSICIANS SHARE THE SAME GOALS AND PREFERENCES?

Author

Dwyer, Lisa, primary, Lin, Dee, additional, Wu, Bingcao, additional, Leblanc, Thomas W, additional, Faiman, Beth, additional, Ahlstrom, Jennifer, additional, Herout, Peter, additional, Deering, Kathleen, additional, Yung, Margaret, additional, Kulbokas, Victoria, additional, Feldman, Josh, additional, Kline, Erika D, additional, and Biran, Noa, additional

Published
2023
Full Text
View/download PDF

27. PB2117: TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY: COMPARATIVE EFFECTIVENESS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Ye, Jing Christine, primary, Biran, Noa, additional, Nair, Sandhya, additional, Lin, Xiwu, additional, Qi, Keqin, additional, Londhe, Anil, additional, Ammann, Eric, additional, Renaud, Thomas, additional, Kane, Colleen, additional, Parekh, Trilok, additional, Gray, Kathleen, additional, Peterson, Steve, additional, and Costa, Luciano, additional

Published
2023
Full Text
View/download PDF

30. Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades

Author

Bangolo, Ayrton I, primary, Fwelo, Pierre, additional, Trivedi, Chinmay, additional, Sagireddy, Sowmya, additional, Aljanaahi, Hamed, additional, Auda, Auda, additional, Mohamed, Maryama, additional, Onyeka, Sonia, additional, Fisher, Miriam, additional, Thapa, Jyoti, additional, Tabucanon, Erwin J, additional, Georgiev, Lyuben, additional, Wishart, Annetta, additional, Kumari, Shilpee, additional, Erikson, Conrad, additional, Bangura, Mary, additional, Paddy, Orent, additional, Madhukar, Rashmi, additional, Gomez, Eugenio L, additional, Rathod, Joshua, additional, Naria, Mansi, additional, Hajal, Basel, additional, Awadhalla, Mohammad, additional, Siegel, David, additional, Parmar, Harsh, additional, Biran, Noa, additional, Vesole, David H, additional, Phull, Pooja, additional, and Weissman, Simcha, additional

Published
2023
Full Text
View/download PDF

31. Abstract CT262: Durable responses following anti-TIGIT (BMS-986207) and anti-LAG3 (BMS-980616) in combination with pomalidomide in relapsed myeloma: MMRF MyCheckpoint trial

Author

Cho, Hearn J., primary, Richard, Shambavi, additional, Lesokhin, Alex, additional, Biran, Noa, additional, Paul, Barry, additional, Vij, Ravi, additional, Pianko, Matthew, additional, Doxie, Deon, additional, Martillo, Mercedes, additional, Wozniak, Katie, additional, Dhodapkar, Kavita, additional, and Dhodapkar, Madhav, additional

Published
2023
Full Text
View/download PDF

34. Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Author

Feinman, Rena, primary, Aptekmann, Ariel A., additional, Colorado, Iriana, additional, Roy, Samuel, additional, Zenreich, Joshua, additional, Dar, Sophia H., additional, Aleman, Adolfo, additional, Unawane, Rashmi, additional, Zhuang, Margaret, additional, Korkoleo, Megan, additional, Vendivil, Mariefel, additional, Ricourt, Andrea, additional, McConnell, Andrew, additional, McKiernan, Phyllis, additional, Dai, Anqi, additional, Pecora, Andrew L., additional, Biran, Noa, additional, Siegel, David, additional, Peled, Jonathan U., additional, and Donato, Michele L., additional

Published
2022
Full Text
View/download PDF

35. Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Author

Oza, Samir, primary, Slotky, Ronit, additional, Vissa, Pranay, additional, Phull, Pooja, additional, Kaur, Sukhdeep, additional, Suh, Hyung C., additional, Donato, Michele L., additional, Rowley, Scott D., additional, Biran, Noa, additional, Vesole, David H., additional, Siegel, David, additional, and Parmar, Harsh, additional

Published
2022
Full Text
View/download PDF

37. The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades

Author

Bangolo, Ayrton, primary, Fwelo, Pierre, additional, Trivedi, Chinmay, additional, Hashem, Jennifer, additional, Jandir, Parul, additional, Klaichart, Katamon, additional, Abdelrahim, Rua, additional, Perera, Ayodya R, additional, Singh, Manbir, additional, Gurumoorthy, Rohini B, additional, Tiwari, Apurva, additional, Konakanchi, Sudha S, additional, Orhun, Nagihan, additional, Polavarapu, Adithya, additional, Sharma, Ritika, additional, Sarkar, Ankit, additional, Gupta, Anupama, additional, Treisma, Bob-Hallen E., additional, Thiri Soe, Thin, additional, Penchala, Ashwin, additional, Penmetsa, Sheetal, additional, Bathi, Srikar, additional, Muppalla, Padmavathi, additional, Siegel, David, additional, Biran, Noa, additional, Parmar, Harsh, additional, Vesole, David H., additional, Weissman, Simcha, additional, and Phull, Pooja, additional

Published
2022
Full Text
View/download PDF

38. The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Author

Kumar, Shaji K, primary, Hofmeister, Craig C, additional, Biran, Noa, additional, Kaur, Gurbakhash, additional, Ye, Jing Christine, additional, Zonder, Jeffrey A., additional, Syed, Umar, additional, Yesil, Jennifer, additional, Woolley, Karen, additional, Mulligan, George, additional, and Cho, Hearn J., additional

Published
2022
Full Text
View/download PDF

39. Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

Author

Baljevic, Muhamed, primary, Gasparetto, Cristina, additional, Schiller, Gary J., additional, Tuchman, Sascha A., additional, Callander, Natalie S., additional, Lentzsch, Suzanne, additional, Monge, Jorge, additional, Kotb, Rami, additional, Bahlis, Nizar J., additional, White, Darrell, additional, Chen, Christine I., additional, Sutherland, Heather J., additional, Madan, Sumit, additional, LeBlanc, Richard, additional, Sebag, Michael, additional, Venner, Christopher P., additional, Bensinger, William I., additional, Biran, Noa, additional, DeCastro, Andrew, additional, Van Domelen, Dane R., additional, Zhang, Chris, additional, Shah, Jatin J., additional, Shacham, Sharon, additional, Kauffman, Michael G., additional, Bentur, Ohad S., additional, and Lipe, Brea, additional

Published
2022
Full Text
View/download PDF

40. OAB-047: Clinical and translational results of the myeloma developing regimens using genomics (MyDRUG) sub-protocol C1 targeting RAS mutations

Author

Kumar, Shaji, primary, Jayasinghe, Reyka, additional, Bianchi, Giada, additional, Biran, Noa, additional, Hultcrantz, Malin, additional, Richter, Joshua, additional, Vij, Ravi, additional, Ye, Christine, additional, Zonder, Jeffrey, additional, DeLello, Lauren, additional, Mulligan, George, additional, Yesil, Jennifer, additional, and Cho, Hearn, additional

Published
2022
Full Text
View/download PDF

41. P-011: A randomized phase 2 study of modakafusp alfa (TAK-573) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with a pilot diversity, equity, and inclusion (DEI) strategy

Author

Kaufman, Jonathan, primary, Atrash, Shebli, additional, Benson, Don, additional, Holstein, Sarah, additional, Nadeem, Omar, additional, Biran, Noa, additional, Suryanarayan, Kaveri, additional, Liu, Yuyin, additional, Robinson, LaShell, additional, Correa, Karen, additional, Enwemadu, Victoria, additional, Parot, Xavier, additional, and Vogl, Dan, additional

Published
2022
Full Text
View/download PDF

42. MM-349 Talquetamab (Tal), a GPRC5D×CD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study

Author

Searle, Emma, Quach, Hang, Biran, Noa, Perrot, Aurore, Berdeja, Jesus G, Dorritie, Kathleen, Van Elssen, Catharina, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, E, Gary, Renaud, Thomas, and Matous, Jeffrey

Published
2024
Full Text
View/download PDF

43. Talquetamab (Tal), a GPRC5D×CD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study

Author

Searle, Emma, Quach, Hang, Biran, Noa, Perrot, Aurore, Berdeja, Jesus G, Dorritie, Kathleen, Van Elssen, Catharina, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, Mason, Gary E, Renaud, Thomas, and Matous, Jeffrey

Published
2024
Full Text
View/download PDF

45. Validation study of end-of-life risk prediction model in active chemotherapy patients.

Author

Hill, Melinda S., primary, Abdo-Matkiwsky, May D., additional, Biran, Noa, additional, Chatiwala, Jumana, additional, Chen, Aileen L., additional, Childs, Julianne Wilkins, additional, Fitzgerald, Denis, additional, Graham, Deena Mary Atieh, additional, Horkheimer, Ian, additional, Levenbach, Rachel L., additional, McLaughlin, Joseph Francis, additional, Salwitz, Kimberly A., additional, Smith, Frederick P., additional, Tassan, Robert F., additional, and Ejumejowo, Akunna J., additional

Published
2022
Full Text
View/download PDF

49. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

Author

Gasparetto, Cristina, primary, Schiller, Gary J., additional, Tuchman, Sascha A., additional, Callander, Natalie S., additional, Baljevic, Muhamed, additional, Lentzsch, Suzanne, additional, Rossi, Adriana C., additional, Kotb, Rami, additional, White, Darrell, additional, Bahlis, Nizar J., additional, Chen, Christine I., additional, Sutherland, Heather J., additional, Madan, Sumit, additional, LeBlanc, Richard, additional, Sebag, Michael, additional, Venner, Christopher P., additional, Bensinger, William I., additional, Biran, Noa, additional, Ammu, Sonia, additional, Ben-Shahar, Osnat, additional, DeCastro, Andrew, additional, Van Domelen, Dane, additional, Zhou, Tianjun, additional, Zhang, Chris, additional, Bentur, Ohad S., additional, Shah, Jatin, additional, Shacham, Sharon, additional, Kauffman, Michael, additional, and Lipe, Brea, additional

Published
2021
Full Text
View/download PDF

50. Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Author

White, Darrell J, primary, Chen, Christine I., additional, Baljevic, Muhamed, additional, Tuchman, Sascha A., additional, Bahlis, Nizar J., additional, Schiller, Gary J., additional, Lipe, Brea, additional, Kotb, Rami, additional, Sutherland, Heather J., additional, Bensinger, William I., additional, Madan, Sumit, additional, Sebag, Michael, additional, Lentzsch, Suzanne, additional, Callander, Natalie S., additional, Biran, Noa, additional, Venner, Christopher P., additional, Leblanc, Richard, additional, Monge, Jorge, additional, Chubar, Evgeni, additional, Tadmor, Tamar, additional, Lavi, Noa, additional, Leiba, Merav, additional, DeCastro, Andrew, additional, Van Domelen, Dane R., additional, Zhang, Chris, additional, Mishal, Moran, additional, Bentur, Ohad S., additional, Shah, Jatin J., additional, Shacham, Sharon, additional, Kauffman, Michael G., additional, and Gasparetto, Cristina J., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results